<DOC>
	<DOCNO>NCT02607631</DOCNO>
	<brief_summary>This Phase II single center , open-label , single arm study patient advance thymic epithelial tumor failure cisplatin-based combination chemotherapy . Patients treat Pembrolizumab 200 mg every 3 week .</brief_summary>
	<brief_title>A Study Pembrolizumab Patients With Thymic Epithelial Tumor</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Thymus Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>1 . Be willing able provide write informed consent/assent trial . 2 . Be 18 year age day sign informed consent . 3 . Histologically proven thymic epithelial tumor ( TET ) patient 4 . Inoperable metastatic disease 5 . More one previous chemotherapy include least one platinumbased regimen 6 . At least one measurable lesion base RECIST 1.1 7 . Patients could submit least one unstained slide evaluate PDL1 expression status ( PDL1 status , positive ( expression &gt; 1percent tumor cell ) negative , prerequiste enrollment . If submit slide unacceptable analysis PDL1 remain slide , patient enrol ) 8 . Have performance status 0 2 ECOG Performance Scale . 9 . Demonstrate adequate organ function define Table 1 . Laboratory test must perform within 10 day date treatment . 10 . Female subject childbearing potential negative urine serum pregnancy within 72 hour prior receive first dose study medication . If urine test positive confirm negative , serum pregnancy test require . 11 . Female subject childbearing potential willing use 2 method birth control surgically sterile , abstain heterosexual activity course study 120 day last dose study medication . Subjects childbearing potential surgically sterilize free menses &gt; 1 year . 12 . Male subject agree use adequate method contraception start first dose study therapy 120 day last dose study therapy . 1 . Is currently participate participate study investigational agent use investigational device within 4 week first dose treatment . 2 . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment . 3 . Has know additional malignancy progress require active treatment . Exceptions include basal cell carcinoma skin , squamous cell carcinoma skin , situ cervical cancer undergone potentially curative therapy . 4 . Has active automimmune disease require systemic treatment within past 3 month document history clinically severe autoimmune disease , syndrome require systemic steroid immunosuppressive agent . Subjects vitiligo resolve childhood asthma/atopy would exception rule . Subjects require intermittent use bronchodilator local steroid injection would exclude study . Subjects hypothyroidism stable hormone replacement Sjorgen 's syndrome exclude study . 5 . Has evidence interstitial lung disease active , noninfectious pneumonitis . 6 . Has active infection require systemic therapy . 7 . Is pregnant breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 120 day last dose trial treatment . 8 . Has know history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) . 9 . Has know active Hepatitis B ( e.g. , HBsAg reactive ) Hepatitis C ( e.g. , HCV RNA [ qualitative ] detect ) . 10 . Has receive live vaccine within 30 day prior first dose trial treatment . 11 . Uncontrolled systemic illness DM , CHF , unstable angina , hypertension arrhythmia 12 . Has know active tuberculosis treat 13 . Has know history hypersensitivity pemborolizumab 14 . Has treatment history wih mAb within 4 week prior first dose trial treatment 15 . Has radiotherapy chemotherapy within 14 day first trial treatment . Subjects receive radiotherapy &gt; 14 day prior randomization must completely recover therapy related AEs/toxicities except peripheral neuropathy less grade II 16 . Has know history psychosis substance abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Thymic epithelial tumor</keyword>
	<keyword>Pembrolizumab</keyword>
</DOC>